Beyond The Numbers: 4 Analysts Discuss NovoCure Stock
Beyond The Numbers: 4 Analysts Discuss NovoCure Stock
數字背後：4位分析師討論Novocure股票
A comprehensive examination of how financial experts...During the last three months, 4 analysts shared their evaluations of NovoCure (NASDAQ:NVCR), revealing diverse outlooks from bullish to bearish.
在過去的三個月中，4位分析師分享了他們對NovoCure（納斯達克股票代碼：NVCR）的評估，揭示了從看漲到看跌的不同前景。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您將找到他們最近的評級摘要，揭示了過去30天中情緒的變化，並將其與前幾個月進行了比較。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.0, along with a high estimate of $24.00 and a low estimate of $20.00. This current average has increased by 6.69% from the previous average price target of $20.62.
分析師提供了更深入的見解，確定了12個月的目標股價，平均目標價爲22.0美元，最高估計爲24.00美元，低估值爲20.00美元。目前的平均價格較之前的平均目標價20.62美元上漲了6.69％。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析師評級：深度分析
A comprehensive examination of how financial experts...
對金融專家如何...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。